Fairfield, Bush & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Fairfield, Bush & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$273K	Sell	611 -15	-2%	-$6.99K	0.15%	108
2025 Q4	$284K	Sell	626 -45	-7%	-$19.4K	0.15%	96
2025 Q3	$263K	Sell	671 -20	-3%	-$8.36K	0.13%	102
2025 Q2	$308K	Hold	691	–	–	0.17%	88
2025 Q1	$335K	Sell	691 -88	-11%	-$41K	0.21%	84
2024 Q4	$314K	Sell	779 -622	-44%	-$288K	0.18%	86
2024 Q3	$652K	Sell	1,401 -445	-24%	-$214K	0.39%	64
2024 Q2	$865K	Sell	1,846 -220	-11%	-$95.5K	0.52%	51
2024 Q1	$864K	Buy	2,066 +670	+48%	+$283K	0.51%	51
2023 Q4	$568K	Buy	+1,396	New	+$516K	0.33%	65
2023 Q3	–	Sell	-16	Closed	-$5.63K	–	507
2023 Q2	$5.63K	Buy	+16	New	+$5.39K	﹤0.01%	366
2022 Q3	–	Sell	-16	Closed	-$5K	–	459
2022 Q2	$5K	Buy	+16	New	+$4.28K	﹤0.01%	356

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fairfield, Bush & Co's VRTX Position: Q1 2026 in Review

Fairfield, Bush & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, selling an estimated $6.99K and leaving 611 shares worth $273K. The position accounts for 0.15% of the portfolio, ranked #108.

Fairfield, Bush & Co first reported a position in VRTX in Q2 2022 and has held it in 12 quarters since. The position peaked at $865K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fairfield, Bush & Co held 611 shares of Vertex Pharmaceuticals worth $273K as of Q1 2026.
Fairfield, Bush & Co sold 15 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.99K.
Vertex Pharmaceuticals made up 0.15% of Fairfield, Bush & Co's portfolio in Q1 2026, its #108 holding.
Fairfield, Bush & Co first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
Fairfield, Bush & Co's Vertex Pharmaceuticals position peaked at $865K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.